GlaxoSmithKline PLC (NYSE:GSK) saw strong trading volume on Wednesday . 4,033,124 shares traded hands during trading, an increase of 20% from the previous session’s volume of 3,370,486 shares.The stock last traded at $44.88 and had previously closed at $44.16.

A number of equities analysts have issued reports on the stock. Shore Capital reissued a “hold” rating on shares of GlaxoSmithKline PLC in a research report on Wednesday. Citigroup Inc. reaffirmed a “buy” rating on shares of GlaxoSmithKline PLC in a report on Wednesday. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Monday. Zacks Investment Research raised shares of GlaxoSmithKline PLC from a “sell” rating to a “hold” rating in a report on Monday. Finally, Jefferies Group raised shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a report on Thursday, July 14th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $46.86.

The firm has a market cap of $109.60 billion and a P/E ratio of 135.09. The stock has a 50 day moving average of $42.61 and a 200 day moving average of $41.42.

The business also recently declared a dividend, which was paid on Thursday, July 14th. Investors of record on Friday, May 13th were issued a dividend of $0.549 per share. The ex-dividend date was Wednesday, May 11th.

Other large investors recently modified their holdings of the company. BlackRock Advisors LLC increased its stake in shares of GlaxoSmithKline PLC by 2,368.8% in the fourth quarter. BlackRock Advisors LLC now owns 345,182 shares of the pharmaceutical company’s stock valued at $13,928,000 after buying an additional 331,200 shares in the last quarter. Morgan Stanley boosted its position in GlaxoSmithKline PLC by 5.8% in the fourth quarter. Morgan Stanley now owns 4,839,818 shares of the pharmaceutical company’s stock valued at $195,287,000 after buying an additional 266,738 shares during the last quarter. Airain ltd acquired a new position in GlaxoSmithKline PLC during the fourth quarter valued at about $3,112,000. Turner Investments L.P. boosted its position in GlaxoSmithKline PLC by 106.7% in the fourth quarter. Turner Investments L.P. now owns 138,100 shares of the pharmaceutical company’s stock valued at $5,573,000 after buying an additional 71,290 shares during the last quarter. Finally, Trexquant Investment LP acquired a new position in GlaxoSmithKline PLC during the fourth quarter valued at about $2,835,000.

GlaxoSmithKline plc. (GSK) is a healthcare company that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The Company operates in two segments: Pharmaceuticals and Vaccines, and Consumer Healthcare. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.